Intellectual Property India Publishes Patent Application for 'Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof' Filed by Pfizer Inc.

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517097515 A) filed by Pfizer Inc., New York, on Oct. 9, for 'immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof.'

Inventor(s) include Bhetuwal, Bishwa Raj; Dutta, Kaushik; Gu, Jianxin; Kapil, Sunayana; Kim, Jin-Hwan; Moran, Justin Keith; Singh, Suddham; and Yang, Yuying.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR(R), SYNFLORIX(R) and/or PREVNAR 13(R). The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions."

The patent application was internationally filed on Apr. 10, 2024, under International application No.PCT/IB2024/053496.

Disclaimer: Curated by HT Syndication.